Daewoong Pharma Asset Resilience Ratio
Daewoong Pharma asset resilience ratio. Daewoong Pharma (069620) has an Asset Resilience Ratio of 0.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Daewoong Pharma to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Daewoong Pharma (2007–2024)
Asset resilience ratio of Daewoong Pharma from 2007 to 2024. This chart shows how Daewoong Pharma's Asset Resilience Ratio has changed over time. Read Daewoong Pharma (069620) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Daewoong Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Daewoong Pharma total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.36 Billion | 0.19% |
| Total Liquid Assets | ₩4.36 Billion | 0.19% |
Asset Resilience Insights
- Limited Liquidity: Daewoong Pharma maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Daewoong Pharma Industry Peers by Asset Resilience Ratio
Compare Daewoong Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Daewoong Pharma Asset Resilience Ratio by Year (2007–2024)
Daewoong Pharma asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Daewoong Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.68% | ₩13.40 Billion ≈ $9.08 Million |
₩1.98 Trillion ≈ $1.34 Billion |
-0.99pp |
| 2023-12-31 | 1.67% | ₩26.18 Billion ≈ $17.74 Million |
₩1.57 Trillion ≈ $1.06 Billion |
-0.74pp |
| 2022-12-31 | 2.41% | ₩37.70 Billion ≈ $25.55 Million |
₩1.56 Trillion ≈ $1.06 Billion |
-4.50pp |
| 2021-12-31 | 6.91% | ₩97.83 Billion ≈ $66.30 Million |
₩1.42 Trillion ≈ $959.05 Million |
-0.76pp |
| 2020-12-31 | 7.67% | ₩104.82 Billion ≈ $71.04 Million |
₩1.37 Trillion ≈ $926.33 Million |
-0.18pp |
| 2019-12-31 | 7.85% | ₩97.74 Billion ≈ $66.23 Million |
₩1.25 Trillion ≈ $844.17 Million |
+2.28pp |
| 2018-12-31 | 5.57% | ₩67.25 Billion ≈ $45.57 Million |
₩1.21 Trillion ≈ $818.54 Million |
+0.96pp |
| 2017-12-31 | 4.61% | ₩55.96 Billion ≈ $37.92 Million |
₩1.21 Trillion ≈ $822.39 Million |
-2.60pp |
| 2016-12-31 | 7.21% | ₩82.56 Billion ≈ $55.95 Million |
₩1.14 Trillion ≈ $775.75 Million |
-2.54pp |
| 2015-12-31 | 9.76% | ₩92.16 Billion ≈ $62.45 Million |
₩944.53 Billion ≈ $640.09 Million |
-7.29pp |
| 2014-12-31 | 17.05% | ₩118.38 Billion ≈ $80.23 Million |
₩694.26 Billion ≈ $470.49 Million |
+10.42pp |
| 2013-12-31 | 6.63% | ₩38.37 Billion ≈ $26.00 Million |
₩579.01 Billion ≈ $392.39 Million |
+6.60pp |
| 2012-12-31 | 0.02% | ₩112.00 Million ≈ $75.90K |
₩482.34 Billion ≈ $326.88 Million |
-4.47pp |
| 2008-12-31 | 4.49% | ₩21.85 Billion ≈ $14.81 Million |
₩486.24 Billion ≈ $329.52 Million |
-0.15pp |
| 2007-12-31 | 4.64% | ₩18.23 Billion ≈ $12.35 Million |
₩392.81 Billion ≈ $266.20 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more